THE HEALTH CORPORATION - RAMBAM

Their core work

Rambam Health Care Campus in Haifa is one of Israel's largest university-affiliated hospitals, contributing real-world clinical expertise, patient cohort access, and clinical validation capacity to EU research consortia. In H2020, they have worked on two distinct clinical challenges: evaluating the economic and clinical value of rapid diagnostics to reduce antibiotic overuse, and building personalised risk models to prevent sudden cardiac death after heart attacks. Their core value to any consortium is access to a high-volume patient population and the clinical infrastructure to validate research hypotheses in a real hospital setting. They do not lead EU projects but serve as a specialist clinical site — collecting data, validating tools, and anchoring research in clinical reality.

What they specialise in

How they've shifted over time

Rambam's H2020 participation began in 2019 with an infectious disease focus — specifically the economics and clinical impact of rapid diagnostics in the context of antimicrobial resistance. By 2020, their second project shifted entirely to cardiology, targeting personalised risk stratification and prevention of sudden cardiac death after myocardial infarction. This is a meaningful shift from population-level infectious disease management toward precision, data-driven cardiovascular medicine. The common thread across both is clinical decision support — improving how clinicians make high-stakes decisions using evidence and data.

Rambam appears to be moving toward personalised medicine and AI-assisted clinical decision tools, suggesting future collaboration opportunities in digital health, precision cardiology, and risk stratification for chronic disease management.

How they like to work

Rambam participates exclusively as a consortium partner — they have never coordinated an H2020 project — which positions them as a specialist clinical contributor rather than a project driver. Despite only two projects, they have engaged with 51 unique partners across 17 countries, indicating they join large, multi-site international consortia where many clinical centres contribute data in parallel. This suggests they are comfortable operating within complex governance structures and are valued for what they bring to the table (patients, clinical infrastructure) rather than for project management capacity.

With 51 unique consortium partners across 17 countries from just two projects, Rambam operates within large-scale international clinical research networks. Their geographic reach extends well beyond Israel into the broader European Research Area, consistent with Israel's association status in Horizon 2020.

What sets them apart

Rambam is one of very few Israeli hospital-level clinical partners active in H2020 health research, giving European consortia access to a high-volume Middle Eastern patient population and clinical expertise outside the EU geography. Their dual experience in infectious disease and cardiovascular medicine makes them versatile across different clinical validation needs. For consortium builders, Rambam offers credibility as a real-world clinical site — not an academic group modelling patients, but a hospital that treats them.

Highlights from their portfolio

• PROFID
  The larger of the two projects (EUR 185,000 received), running until 2026, it tackles one of cardiology's hardest problems — predicting which post-heart-attack patients will die suddenly — using personalised risk models and a clinical decision tool.
• VALUE-Dx
  Addresses antimicrobial resistance through a health economics lens, making Rambam a clinical validation partner in a globally critical public health challenge with direct policy implications for antibiotic prescribing.